Literature DB >> 26068654

Antihypertensive Combination Treatment: State of the Art.

M Burnier1.   

Abstract

An adequate control of blood pressure is essential to reduce the risk of target organ damages and cardiovascular events in patients with hypertension. Yet, it is well recognized that a substantial proportion of treated patients remain hypertensive despite treatment. Several reasons have been evoked to explain why so many patients are not adequately controlled. Among them, medical inertia, a poor long-term adherence, and the need to prescribe several antihypertensive drugs to reach the target blood pressure have been identified as major limitations to the success of antihypertensive therapy. In this context, the use of single-pill combinations (SPC) containing two or three drugs in one pill has an important role in reducing the impact of some of these issues. Indeed, the use of SPC enables to reduce the pill burden and to improve the treatment efficacy without increasing the incidence of side effects. However, besides their major advantages, SPC have also some limitations such as a possible lack of flexibility or a higher cost. The purpose of this review is to discuss the place of SPC in the actual management of hypertension. The active development of new single-pill combinations in last years can be considered as a significant improvement in the physicians' capacity to treat hypertension effectively.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26068654     DOI: 10.1007/s11906-015-0562-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  63 in total

1.  Fixed-dose combinations improve medication compliance: a meta-analysis.

Authors:  Sripal Bangalore; Gayathri Kamalakkannan; Sanobar Parkar; Franz H Messerli
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

2.  Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.

Authors:  M Burnier; Y Brede; A Lowy
Journal:  Int J Clin Pract       Date:  2011-01-06       Impact factor: 2.503

3.  Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.

Authors:  L V Franse; M Pahor; M Di Bari; G W Somes; W C Cushman; W B Applegate
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

4.  Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes.

Authors:  D J Campbell; M McGrady; D L Prior; J M Coller; U Boffa; L Shiel; D Liew; R Wolfe; S Stewart; C M Reid; H Krum
Journal:  Intern Med J       Date:  2013-02       Impact factor: 2.048

Review 5.  Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.

Authors:  A de la Sierra
Journal:  J Hum Hypertens       Date:  2009-01-15       Impact factor: 3.012

6.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

Authors:  Sayed H Naderi; Jonathan P Bestwick; David S Wald
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

7.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

Review 8.  The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis.

Authors:  Pinar Kizilirmak; Mehmet Berktas; Yagiz Uresin; Okan Bulent Yildiz
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-12-14       Impact factor: 3.738

9.  Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill.

Authors:  Michel Burnier
Journal:  Integr Blood Press Control       Date:  2010-05-27

Review 10.  Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.

Authors:  Mario Malerba; Jaymin Bhagwanji Morjaria; Alessandro Radaeli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-06-27
View more
  6 in total

Review 1.  Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Authors:  Nicolás Renna; Daniel Piskorz; Diego Stisman; Diego Martinez; Ludmila Lescano; Sergio Vissani; Walter Espeche; Diego Marquez; Roberto Parodi; Diego Naninni; Marcos Baroni; Daniel Llanos; Rocio Martinez; Jessica Barochinner; Gustavo Staffieri; Fernando Lanas; Mónica Velásquez; Marcos Marin; Bryan Williams; Irene Ennis
Journal:  J Hum Hypertens       Date:  2021-06-04       Impact factor: 3.012

2.  How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014).

Authors:  Andrea L Schaffer; Sallie-Anne Pearson; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

3.  Comparison of therapy persistence for fixed versus free combination antihypertensives: a retrospective cohort study.

Authors:  Thomas Grimmsmann; Wolfgang Himmel
Journal:  BMJ Open       Date:  2016-11-22       Impact factor: 2.692

4.  Evaluation of Blood Pressure Control and Associated Factors among Patients with Hypertension in Iraq: A Prospective Cross-sectional Study.

Authors:  Ola Ali Nassr; Paul Forsyth
Journal:  J Pharm Bioallied Sci       Date:  2019 Jul-Sep

5.  Fixed Versus Free Combinations Of Antihypertensive Drugs: Analyses Of Real-World Data Of Persistence With Therapy In Italy.

Authors:  Daria Putignano; Valentina Orlando; Valeria Marina Monetti; Gaetano Piccinocchi; Umberto Maria Musazzi; Roberto Piccinocchi; Paola Minghetti; Enrica Menditto
Journal:  Patient Prefer Adherence       Date:  2019-11-11       Impact factor: 2.711

Review 6.  Combination therapy in the treatment of hypertension.

Authors:  Carolina Guerrero-García; Alberto Francisco Rubio-Guerra
Journal:  Drugs Context       Date:  2018-06-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.